Sustained remission of treatment-resistant cutaneous T-cell lymphoma with oral bexarotene

被引：0
|
作者：
Mehlmauer, MA [1 ]
机构：
[1] Huntington Mem Hosp, Pasadena, CA USA
来源：
CUTIS | 2004年 / 73卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Cutaneous T-cell lymphomas (CTCL) encompass a spectrum of clinical and histologic variants, characterized by malignant CD4+ T lymphocytes in the skin and visceral organs. This is a case report of a 74-year-old man with CTCL, including ulcerative lesions, resistant to multiple systemic therapies. Treatment with oral bexarotene resulted in rapid and sustained remission of both cutaneous and systemic symptoms.
引用
收藏
页码：417 / 420
页数：4
相关论文
共 50 条
  • [21] Dyslipidaemia in patients with cutaneous T-cell lymphoma treated with bexarotene
    Eagle, M.
    Whittaker, S. J.
    Morris, S. L.
    Wierzbiki, A.
    Scarisbrick, J.
    BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 : 46 - 47
  • [22] ORAL VORINOSTAT COMBINED WITH BEXAROTENE IN ADVANCED CUTANEOUS T-CELL LYMPHOMA: A PHASE I STUDY
    Dummer, R.
    Hymes, K.
    Sterry, W.
    Steinhoff, M.
    Assaf, C.
    Kerl, H.
    Ahern, J.
    Rizvi, S.
    Ricker, J.
    Whittaker, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 170 - 171
  • [23] PHASE I TRIAL OF ORAL VORINOSTAT IN COMBINATION WITH BEXAROTENE IN ADVANCED CUTANEOUS T-CELL LYMPHOMA
    Dummer, R.
    Hymes, K.
    Sterry, W.
    Steinhoff, M.
    Assaf, C.
    Kerl, H.
    Ahern, J.
    Rizvi, S.
    Ricker, J. L.
    Whittaker, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 110 - 110
  • [24] Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma
    T Illidge
    C Chan
    N Counsell
    S Morris
    J Scarisbrick
    D Gilson
    B Popova
    P Patrick
    P Smith
    S Whittaker
    R Cowan
    British Journal of Cancer, 2013, 109 : 2566 - 2573
  • [25] Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma
    Illidge, T.
    Chan, C.
    Counsell, N.
    Morris, S.
    Scarisbrick, J.
    Gilson, D.
    Popova, B.
    Patrick, P.
    Smith, P.
    Whittaker, S.
    Cowan, R.
    BRITISH JOURNAL OF CANCER, 2013, 109 (10) : 2566 - 2573
  • [26] Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma
    Kannangara, Ajith P.
    Levitan, Denise
    Fleischer, Alan B., Jr.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2009, 20 (03) : 169 - 176
  • [27] Experience with bexarotene in cutaneous T-cell lymphoma: A collaborative study of the Spanish Group of Cutaneous Lymphoma
    Izu, Rosa
    Yanguas, Ignacio
    Servitje, Octavio
    Ortiz, Pablo
    Fernandez de Misa, Ricardo
    Estrach, Teresa
    Monsalvez, Veronica
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB123 - AB123
  • [28] Bexarotene monotherapy and combination therapy for cutaneous T-cell lymphoma.
    Talpur, R
    Ward, S
    Apisarnthanarax, N
    Duvic, M
    BLOOD, 2001, 98 (11) : 132A - 132A
  • [29] Thyroid and lipidic dysfunction associated with bexarotene in cutaneous T-cell lymphoma
    Rodriguez Suarez, Santiago
    Pamies Andreu, Encarnacion
    Muniz Grijalvo, Ovidio
    Garcia Morillo, Jose Salvador
    MEDICINA CLINICA, 2016, 146 (03): : 117 - 120
  • [30] Phase I trial of oral vorinostat in combination with bexarotene in patients with advanced cutaneous T-cell lymphoma
    Hymes, K.
    Dummer, R.
    Sterry, W.
    Steinhoff, M.
    Assaf, C.
    Kerl, H.
    Ahern, J.
    Rizvi, S.
    Ricker, J. L.
    Whittaker, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345